Kypha

Preeclampsia is a serious blood pressure condition that can develop after the 20th week of pregnancy and requires rapid medical intervention to prevent life-threatening complications. It is estimated to affect between 5-8% of all live births in the United States. In one recent study soluble C5b-9 complement protein was found to be elevated in the urine of 96% of patients with preeclampsia, and this may be helpful for differential diagnosis and assessing risk of organ damage. Unfortunately this kind of information typically cannot be delivered fast enough from standard complement tests. Exacerbating this challenge, many existing complement testing platforms are not optimized for urine testing, and they cannot be paired easily with other essential test results. At Kypha, we are building a rapid, modular multiplex system capable of delivering optimized results in just minutes. Find out more at https://lnkd.in/eksw3Zk6 #complement #cytokines #clinicaltrials #biomarkers #immunebiomarkers #diagnostics #complementdiagnostics #cytokinediagnostics #immunemonitoring #realtimediagnostics #pointofcare #preeclampsia

Complement tests are much more powerful in combination. And evaluating complement system complexity in a more comprehensive manner improves sensitivity and specificity and helps uncover deeper insights into the underlying pathophysiology. For example, studies in rheumatology and hematology demonstrate prognostic and disease monitoring biomarker utility for complement panels such as iC3b/C3 ratio, or sC5b-9 and Ba combinations in blood and urine. As the saying goes: ‘The whole is greater than the sum of its parts’. That’s how Kypha’s multiplex panels with complement and other immune biomarker analytes can deliver immune insights at the point of care. Find out more at https://lnkd.in/eN3hGqwF #complement #cytokines #clinicaltrials #biomarkers #immunebiomarkers #diagnostics #complementdiagnostics #cytokinediagnostics #immunemonitoring #realtimediagnostics #pointofcare #multiplex

Kypha is pleased to announce a new contract to support Prenosis, an artificial intelligence company, in enabling precision medicine for abnormal immune responses in acute care. Understanding acute immune responses, as in sepsis, requires additional diagnostic tools for supporting and improving clinical decision making. Sepsis is the body's extreme immune response to an infection and it is a life-threatening medical emergency. It happens when an existing infection triggers a chain reaction throughout your body, leading to uncontrolled inflammation and multi-organ dysfunction or failure. Each year, more than 1.7 million adults in America develop sepsis and at least 350,000 die during their hospitalization or are discharged to hospice. 1 in 3 people who die in a hospital had sepsis during that hospitalization. Kypha will support Prenosis by leveraging Kypha’s proprietary technology platform, RapiPlex™, and our unique expertise in developing quantitative point-of-care assays. The goal is to deliver a blood test measuring multiple immune and inflammatory response proteins selected for their potential to support faster, more precise diagnosis of sepsis in critical care patients. Ultimately it is hoped that faster diagnosis of this life-threatening condition will facilitate improved therapy decisions and patient outcomes. #ArtificialIntelligence #immunediagnostics #complement #diagnostics #clinicaltrials #immunemonitoring #sepsis #CDC

Complement tests are much more powerful in combination. And evaluating complement system complexity in a more comprehensive manner improves sensitivity and specificity and helps uncover deeper insights into the underlying pathophysiology. For example, studies in rheumatology and hematology demonstrate prognostic and disease monitoring biomarker utility for complement panels such as iC3b/C3 ratio, or sC5b-9 and Ba combinations in blood and urine. As the saying goes: ‘The whole is greater than the sum of its parts’. That’s how Kypha’s multiplex panels with complement and other immune biomarker analytes can deliver immune insights at the point of care. Find out more at https://lnkd.in/eN8wa6Jb #complement #cytokines #clinicaltrials #biomarkers #immunebiomarkers #diagnostics #complementdiagnostics #cytokinediagnostics #immunemonitoring #realtimediagnostics #pointofcare #multiplex

The ability of tumors to escape control – either from the immune system, or from anticancer drugs – has been well-described in recent years. For example, malignant melanoma cells can escape the attention of the innate immune response by increasing complement regulatory protein surface expression and reducing complement deposition and cell removal. Assessing treatment resistant tumor types should include evaluation of complement activation biomarkers. At Kypha our technology is designed to help address these kinds of important questions. Find out more at https://lnkd.in/es-TNXW9 #complement #cytokines #clinicaltrials #biomarkers #immunebiomarkers #diagnostics #complementdiagnostics #cytokinediagnostics #immunemonitoring #realtimediagnostics #cancer #cancerresistance

The ability of tumors to escape control – either from the immune system, or from anticancer drugs – has been well-described in recent years. For example, malignant melanoma cells can escape the attention of the innate immune response by increasing complement regulatory protein surface expression and reducing complement deposition and cell removal. Assessing treatment resistant tumor types should include evaluation of complement activation biomarkers. At Kypha our technology is designed to help address these kinds of important questions. Find out more at https://lnkd.in/e3j6ARnK #complement #cytokines #clinicaltrials #biomarkers #immunebiomarkers #diagnostics #complementdiagnostics #cytokinediagnostics #immunemonitoring #realtimediagnostics #cancer #cancerresistance

Induction of IL-6 can be dependent upon complement activation. In a model of sepsis (Riedemann et al, 2004) the presence of complement factor C5a approximately doubled IL-6 gene expression and protein release from neutrophils. What if managing serious challenges such as cytokine release syndrome, CAR-T toxicity, or other conditions could be improved by the ability to obtain accurate complement and cytokine measurements …in a timely manner? That’s what Kypha’s rapid-test platform is designed to deliver. Find out more at https://lnkd.in/eYn-QAWN #complement #cytokines #clinicaltrials #biomarkers #immunebiomarkers #diagnostics #complementdiagnostics #cytokinediagnostics #immunemonitoring #realtimediagnostics #cytokinestorm

Induction of IL-6 can be dependent upon complement activation. In a model of sepsis (Riedemann et al, 2004) the presence of complement factor C5a approximately doubled IL-6 gene expression and protein release from neutrophils. What if managing serious challenges such as cytokine release syndrome, CAR-T toxicity, or other conditions could be improved by the ability to obtain accurate complement and cytokine measurements …in a timely manner? That’s what Kypha’s rapid-test platform is designed to deliver. Find out more at https://lnkd.in/eYn-QAWN #complement #cytokines #clinicaltrials #biomarkers #immunebiomarkers #diagnostics #complementdiagnostics #cytokinediagnostics #immunemonitoring #realtimediagnostics #cytokinestorm

We’re excited to announce a new addition to our leadership team! We are pleased to welcome David Merselis as the Head of Engineering and Product Management at Kypha, Inc. With years of engineering, operations, and product management experience in the automotive and medical device industries, he brings a proven track record of driving innovation and delivering exceptional results. At Kypha, he will lead our engineering and product teams, focusing on enhancing our offerings and ensuring we meet the needs of our customers. We’re thrilled to have David on board and look forward to the exciting developments ahead! #immunemonitoring #diagnostics #complement #complementdiagnostics #realtimediagnostics

Induction of IL-6 can be dependent upon complement activation. In a model of sepsis (Riedemann et al, 2004) the presence of complement factor C5a approximately doubled IL-6 gene expression and protein release from neutrophils. What if managing serious challenges such as cytokine release syndrome, CAR-T toxicity, or other conditions could be improved by the ability to obtain accurate complement and cytokine measurements …in a timely manner? That’s what Kypha’s rapid-test platform is designed to deliver. Find out more at https://lnkd.in/eFY_nxJC #complement #cytokines #clinicaltrials #biomarkers #immunebiomarkers #diagnostics #complementdiagnostics #cytokinediagnostics #immunemonitoring #realtimediagnostics #cytokinestorm